Plasma norepinephrine is an independent predictor of adverse cerebral and cardiovascular events in type 2 diabetic patients without structural heart disease

Journal of Cardiology

Volumn 64, Issue 3, 2014, Pages 225-230

  Yufu, Kunio ^a   Okada, Norihiro ^a   Ebata, Yuki ^a   Murozono, Yukichi ^a   Shinohara, Tetsuji ^a   Nakagawa, Mikiko ^a   Takahashi, Naohiko ^a  

^a OITA UNIVERSITY   (Japan)

Author keywords

Autonomic nervous system; Cardiovascular event; Diabetes mellitus; Norepinephrine

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; NORADRENALIN; BIOLOGICAL MARKER;

ACCURACY; ADULT; ADVERSE OUTCOME; AREA UNDER THE CURVE; ARTICLE; BODY MASS; BRAIN DISEASE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CONGESTIVE HEART FAILURE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART DEATH; HEART INFARCTION; HEART SCINTISCANNING; HIGH RISK PATIENT; HUMAN; HYPERURICEMIA; JAPANESE (PEOPLE); KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; NORADRENALIN BLOOD LEVEL; PREDICTIVE VALUE; PREDICTOR VARIABLE; PRESSORECEPTOR REFLEX; RECEIVER OPERATING CHARACTERISTIC; SEX DIFFERENCE; AGED; BLOOD; CARDIOVASCULAR DISEASES; COMPLICATION; FORECASTING; HEART FAILURE; INCIDENCE; PHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; REST; RISK; RISK ASSESSMENT; STROKE; TIME;

AGED; BAROREFLEX; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; FOLLOW-UP STUDIES; FORECASTING; HEART FAILURE; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NOREPINEPHRINE; PROPORTIONAL HAZARDS MODELS; REST; RISK; RISK ASSESSMENT; ROC CURVE; SEX FACTORS; STROKE; TIME FACTORS;

EID: 84926251870     PISSN: 09145087     EISSN: 18764738     Source Type: Journal    
DOI: 10.1016/j.jjcc.2013.12.009     Document Type: Article

References (30)

1. Takahashi N., Nakagawa M., Saikawa T., Ooie T., Yufu K., Shigematsu S., Hara M., Sakino H., Katsuragi I., Okeda T., Yoshimatsu H., Sakata T. Effect of essential hypertension on cardiac autonomic function in type 2 diabetic patients. J Am Coll Cardiol 2001, 38:232-237.
2. Takahashi N., Anan F., Nakagawa M., Yufu K., Ooie T., Nawata T., Shigematsu S., Hara M., Saikawa T., Yoshimatsu H. Microalbuminuria, cardiovascular autonomic dysfunction, and insulin resistance in patients with type 2 diabetes mellitus. Metabolism 2004, 53:1359-1364.
3. Anan F., Takahashi N., Nakagawa M., Yufu K., Ooie T., Nawata T., Shigematsu S., Hara M., Saikawa T., Yoshimatsu H. High-sensitivity C-reactive protein is associated with insulin resistance and cardiovascular autonomic dysfunction in type 2 diabetic patients. Metabolism 2005, 54:552-558.
4. Yufu K., Takahashi N., Nakagawa M., Hara M., Saikawa T., Yoshimatsu H. Brain natriuretic peptide and cardiac autonomic function in type 2 diabetic patients. Diabetes Res Clin Pract 2006, 72:12-19.
5. Takahashi N., Anan F., Nakagawa M., Yufu K., Shinohara T., Tsubone T., Goto K., Masaki T., Katsuragi I., Tanaka K., Kakuma T., Hara M., Saikawa T., Yoshimatsu Hypoadiponectinemia in type 2 diabetes mellitus in men is associated with sympathetic overactivity as evaluated by cardiac 123I-metaiodobenzylguanidine scintigraphy. Metabolism 2007, 56:919-924.
6. Okada N., Takahashi N., Murozono Y., Wakisaka O., Shinohara T., Anan F., Nakagawa M., Hara M., Saikawa T., Yoshimatsu H. Baroreflex sensitivity predicts cardiovascular events in patients with type 2 diabetes mellitus without structural heart disease. Circ J 2010, 74:1379-1383.
7. Wieland D.M., Brown L.E., Rogers W.L., Worthington K.C., Wu J.L., Clinthorne N.H., Otto C.A., Swanson D.P., Beierwaltes W.H. Myocardial imaging with a radioiodinated norepinephrine storage analog. J Nucl Med 1981, 22:22-31.
8. Henderson E.B., Kahn J.K., Corbett J.R., Jansen D.E., Pippin J.J., Kulkarni P., Ugolini V., Akers M.S., Hansen C., Buja L.M., Parkey R.W., Willerson J.T. Abnormal I-123 metaiodobenzylguanidine myocardial washout and distribution may reflect myocardial adrenergic derangement in patients with congestive cardiomyopathy. Circulation 1988, 78:1192-1199.
9. Yufu K., Takahashi N., Okada N., Shinohara T., Nakagawa M., Hara M., Yoshimatsu H., Saikawa T. Cardiac iodine-123 metaiodobenzylguanidine (123I-MIBG) scintigraphy parameter predicts cardiac and cerebrovascular events in type 2 diabetic patients without structural heart disease. Circ J 2012, 76:399-404.
10. Benedict C.R., Shelton B., Johnstone D.E., Francis G., Greenberg B., Konstam M., Probstfield J.L., Yusuf S. Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. SOLVD Investigators. Circulation 1996, 94:690-697.
11. Cohn J.N., Levine T.B., Olivari M.T., Garberg V., Lura D., Francis G.S., Simon A.B., Rector T. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984, 311:819-823.
12. Rouleau J.L., Packer M., Moyé L., de Champlain J., Bichet D., Klein M., Rouleau J.R., Sussex B., Arnold J.M., Sestier F., Parker J.O., McEwan P., Bernstein V., Cuddy T.E., Lamas G., et al. Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril. J Am Coll Cardiol 1994, 24:583-591.
13. Kuzuya T., Nakagawa S., Satoh J., Kanazawa Y., Iwamoto Y., Kobayashi M., Nanjo K., Sasaki A., Seino Y., Ito C., Shima K., Nonaka K., Kadowaki T. Report of the committee on the classification and diagnostic criteria of diabetes mellitus. Diabetes Res Clin Pract 2002, 55:65-85.
14. La Rovere M.T., Bigger J.T., Marcus F.I., Mortara A., Schwartz P.J. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. ATRAMI (Autonomic Tone and Reflexes After Myocardial Infarction) Investigators. Lancet 1998, 351:478-484.
15. Liao D., Sloan R.P., Cascio W.E., Folsom A.R., Liese A.D., Evans G.W., Cai J., Sharrett A.R. Multiple metabolic syndrome is associated with lower heart rate variability. The Atherosclerosis Risk in Communities Study. Diabetes Care 1998, 21:2116-2122.
16. Hakoda M., Masunari N., Yamada M., Fujiwara S., Suzuki G., Kodama K., Kasagi F. Serum uric acid concentration as a risk factor for cardiovascular mortality. J Rheumatol 2005, 32:906-912.
17. National Kidney Foundation K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002, 39:S1-S266.
18. Nagamachi S., Jinnouchi S., Kurose T., Ohnishi T., Flores L.G., Nakahara H., Futami S., Tamura S., Matsukura S. 123I-MIBG myocardial scintigraphy in diabetic patients: relationship with 201Tl uptake and cardiac autonomic function. Ann Nucl Med 1998, 12:323-331.
19. Murozono Y., Yufu K., Takahashi N., Okada N., Shinohara T., Nakagawa M., Hara M., Saikawa T. Combined assessment of baroreflex sensitivity with iodine 123 metaiodobenzylguanidine scintigraphic findings strengthens the power of predictive value for cerebral and cardiovascular events in type 2 diabetic patients. Circ J 2012, 77:130-136.
20. Sakata K., Shirotani M., Yoshida H., Kurata C. Cardiac sympathetic nervous system in early essential hypertension assessed by 123I-MIBG. J Nucl Med 1999, 40:6-11.
21. Cohn J.N. Mechanisms in heart failure and the role of angiotensin-converting enzyme inhibition. Am J Cardiol 1990, 66:2D-6D.
22. Francis G.S., McDonald K.M., Cohn J.N. Neurohumoral activation in preclinical heart failure. Remolding and the potential for intervention. Circulation 1993, 87:IV90-IV96.
23. Benedict C.R. Neurohumoral aspects of heart failure. Cardiol Clin North Am 1994, 12:9-23.
24. Martin E.A., Prasad A., Rihal C.S., Lerman L.O., Lerman A. Endothelial function and vascular response to mental stress are impaired in patients with apical ballooning syndrome. J Am Coll Cardiol 2010, 56:1840-1846.
25. Watanabe S., Amiya E., Watanabe M., Takata M., Ozeki A., Watanabe A., Kawarasaki S., Nakao T., Hosoya Y., Omori K., Maemura K., Komuro I., Nagai R. Simultaneous heart rate variability monitoring enhances the predictive value of flow-mediated dilation in ischemic heart disease. Circ J 2013, 77:1018-1025.
26. Hori M., Okamoto H. Heart rate as a target of treatment of chronic heart failure. J Cardiol 2012, 60:86-90.
27. Takahama H., Yokoyama H., Kada A., Sekiguchi K., Fujino M., Funada A., Amaki M., Hasegawa T., Asakura M., Kanzaki H., Anzai T., Kitakaze M. Extent of heart rate reduction during hospitalization using beta-blockers, not the achieved heart rate itself at discharge, predicts the clinical outcome in patients with acute heart failure syndromes. J Cardiol 2013, 61:58-64.
28. Huxley R., Barzi F., Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ 2006, 332:73-78.
29. Yufu K., Takahashi N., Okada N., Wakisaka O., Shinohara T., Nakagawa M., Hara M., Yoshimatsu H., Saikawa T. Gender difference in baroreflex sensitivity to predict cardiac and cerebrovascular events in type 2 diabetic patients. Circ J 2011, 75:1418-1423.
30. Kinugawa T., Ogino K., Osaki S., Kato M., Igawa O., Hisatome I., Fujita M., Shigemasa C. Prognostic significance of exercise plasma noradrenaline levels for cardiac death in patients with mild heart failure. Circ J 2002, 66:261-266.